Missing: Cytogel's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Cytogel's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Cytogel News
Oct 15, 2021
Patrick J. Kennedy Former Congressman Kennedy champions safer & non-addictive pain management as CYT-1010, an alternative to classical opioids, is entering Phase 2 Clinical Trials The Former Congressman’s years of distinguished advocacy have given him an impactful voice to help drive forward our mutual mission of providing a safer, non-addictive option for pain management.” — … Continue reading "Cytogel Announces Former U.S. Congressman Patrick J. Kennedy Joins its Advisory Board"
Cytogel Frequently Asked Questions (FAQ)
When was Cytogel founded?
Cytogel was founded in 2000.
Where is Cytogel's headquarters?
Cytogel's headquarters is located at 46 Station Street, Southport.
What is Cytogel's latest funding round?
Cytogel's latest funding round is Other Investors.
Who are the investors of Cytogel?
Investors of Cytogel include Centripetal Capital Partners.
Who are Cytogel's competitors?
Competitors of Cytogel include PharmaJet, Hutchison MediPharma, Valeritas, Pantec Biosolutions, Azaya Therapeutics and 11 more.
Compare Cytogel to Competitors
The Liposome Company is developing liposome-based drug delivery
BioValve offers drug delivery systems
UMD aims to develop drug delivery technologies and products, with a focus on women's health.
Depotech is developing methods for drug delivery
Replenish Inc is a Pasadena, Calif.-based developer of a drug delivery platform.
AerovectRx is an aerosol therapeutic company providing effective and dosage-controlled drug delivery using the respiratory system as the gateway for better health. Products under development by AerovectRx are designed to deliver a wide variety of therapies through multiple-use mass immunization as well as personal-use nebulizers. Potential targeted therapeutic candidates for the AerovectRx technology include treatments for asthma, cystic fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), diabetes, pain management, and for delivery of vaccines and anti-viral drugs.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.